Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis

Stem cell transplantation (SCT), an effective therapy for amyloid light chain (AL) amyloidosis patients, is associated with low treatment-related mortality (TRM) with appropriate patient selection and risk-adapted dosing of melphalan (RA-SCT). Consolidation after SCT increases hematologic complete r...

Descripción completa

Detalles Bibliográficos
Autores principales: Landau, H, Smith, M, Landry, C, Chou, J F, Devlin, S M, Hassoun, H, Bello, C, Giralt, S, Comenzo, R L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220129/
https://www.ncbi.nlm.nih.gov/pubmed/27560108
http://dx.doi.org/10.1038/leu.2016.229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220129/
https://www.ncbi.nlm.nih.gov/pubmed/27560108
http://dx.doi.org/10.1038/leu.2016.229

Ejemplares similares